192 related articles for article (PubMed ID: 32669316)
1. The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer-Containing Antibody-Drug Conjugates.
Corbett S; Huang S; Zammarchi F; Howard PW; van Berkel PH; Hartley JA
Mol Cancer Ther; 2020 Sep; 19(9):1856-1865. PubMed ID: 32669316
[TBL] [Abstract][Full Text] [Related]
2. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.
Flynn MJ; Zammarchi F; Tyrer PC; Akarca AU; Janghra N; Britten CE; Havenith CE; Levy JN; Tiberghien A; Masterson LA; Barry C; D'Hooge F; Marafioti T; Parren PW; Williams DG; Howard PW; van Berkel PH; Hartley JA
Mol Cancer Ther; 2016 Nov; 15(11):2709-2721. PubMed ID: 27535974
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine.
Hartley JA; Flynn MJ; Bingham JP; Corbett S; Reinert H; Tiberghien A; Masterson LA; Antonow D; Adams L; Chowdhury S; Williams DG; Mao S; Harper J; Havenith CEG; Zammarchi F; Chivers S; van Berkel PH; Howard PW
Sci Rep; 2018 Jul; 8(1):10479. PubMed ID: 29992976
[TBL] [Abstract][Full Text] [Related]
4. Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR.
Mao S; Chaerkady R; Yu W; D'Angelo G; Garcia A; Chen H; Barrett AM; Phipps S; Fleming R; Hess S; Koopmann JO; Dimasi N; Wilson S; Pugh K; Cook K; Masterson LA; Gao C; Wu H; Herbst R; Howard PW; Tice DA; Cobbold M; Harper J
Mol Cancer Ther; 2021 Mar; 20(3):541-552. PubMed ID: 33653945
[TBL] [Abstract][Full Text] [Related]
5. Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
Chang CH; Wang Y; Zalath M; Liu D; Cardillo TM; Goldenberg DM
Mol Cancer Ther; 2016 Aug; 15(8):1910-9. PubMed ID: 27207776
[TBL] [Abstract][Full Text] [Related]
6. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
Zammarchi F; Corbett S; Adams L; Tyrer PC; Kiakos K; Janghra N; Marafioti T; Britten CE; Havenith CEG; Chivers S; D'Hooge F; Williams DG; Tiberghien A; Howard PW; Hartley JA; van Berkel PH
Blood; 2018 Mar; 131(10):1094-1105. PubMed ID: 29298756
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy.
Hartley JA
Expert Opin Biol Ther; 2021 Jul; 21(7):931-943. PubMed ID: 32543981
[TBL] [Abstract][Full Text] [Related]
8. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Takegawa N; Nonagase Y; Yonesaka K; Sakai K; Maenishi O; Ogitani Y; Tamura T; Nishio K; Nakagawa K; Tsurutani J
Int J Cancer; 2017 Oct; 141(8):1682-1689. PubMed ID: 28677116
[TBL] [Abstract][Full Text] [Related]
9. Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
White JB; Fleming R; Masterson L; Ruddle BT; Zhong H; Fazenbaker C; Strout P; Rosenthal K; Reed M; Muniz-Medina V; Howard P; Dixit R; Wu H; Hinrichs MJ; Gao C; Dimasi N
MAbs; 2019 Apr; 11(3):500-515. PubMed ID: 30835621
[TBL] [Abstract][Full Text] [Related]
10. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT; Ungar D; He S; Boni J; Havenith K; O'Connor OA
Clin Cancer Res; 2019 Dec; 25(23):6986-6994. PubMed ID: 31685491
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers.
Zammarchi F; Havenith KE; Chivers S; Hogg P; Bertelli F; Tyrer P; Janghra N; Reinert HW; Hartley JA; van Berkel PH
Mol Cancer Ther; 2022 Apr; 21(4):582-593. PubMed ID: 35086955
[TBL] [Abstract][Full Text] [Related]
12. SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
Kinneer K; Meekin J; Tiberghien AC; Tai YT; Phipps S; Kiefer CM; Rebelatto MC; Dimasi N; Moriarty A; Papadopoulos KP; Sridhar S; Gregson SJ; Wick MJ; Masterson L; Anderson KC; Herbst R; Howard PW; Tice DA
Clin Cancer Res; 2018 Dec; 24(24):6570-6582. PubMed ID: 30131388
[TBL] [Abstract][Full Text] [Related]
13. Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody-Drug Conjugates.
Staben LR; Chen J; Cruz-Chuh JD; Del Rosario G; Go MA; Guo J; Khojasteh SC; Kozak KR; Li G; Ng C; Lewis Phillips GD; Pillow TH; Rowntree RK; Wai J; Wei B; Xu K; Xu Z; Yu SF; Zhang D; Dragovich PS
J Med Chem; 2020 Sep; 63(17):9603-9622. PubMed ID: 32787101
[TBL] [Abstract][Full Text] [Related]
14. Improved Therapeutic Window in
Zhong H; Chen C; Tammali R; Breen S; Zhang J; Fazenbaker C; Kennedy M; Conway J; Higgs BW; Holoweckyj N; Raja R; Harper J; Pierce AJ; Herbst R; Tice DA
Mol Cancer Ther; 2019 Jan; 18(1):89-99. PubMed ID: 30352801
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy.
Tarantelli C; Wald D; Munz N; Spriano F; Bruscaggin A; Cannas E; Cascione L; Gaudio E; Arribas AJ; Manjappa S; Golino G; Scalise L; Cacciapuoti MT; Zucca E; Stathis A; Inghirami G; Van Berkel PH; Rossi D; Caimi PF; Zammarchi F; Bertoni F
Haematologica; 2024 May; ():. PubMed ID: 38721745
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
[TBL] [Abstract][Full Text] [Related]
17. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
[TBL] [Abstract][Full Text] [Related]
18. ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies.
Zammarchi F; Havenith KE; Sachini N; Janghra N; Chivers S; Idusogie E; Gaudio E; Tarantelli C; Bertelli F; Santos K; Tyrer P; Corbett S; Spriano F; Golino G; Cascione L; Bertoni F; Hartley JA; van Berkel PH
Mol Cancer Ther; 2024 Apr; 23(4):520-531. PubMed ID: 38324336
[TBL] [Abstract][Full Text] [Related]
19. Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.
Xu B
Eur J Clin Pharmacol; 2022 May; 78(5):707-719. PubMed ID: 35061047
[TBL] [Abstract][Full Text] [Related]
20. What's new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?
Hartley JA
Expert Opin Biol Ther; 2023; 23(11):1049-1052. PubMed ID: 37902460
[No Abstract] [Full Text] [Related]
[Next] [New Search]
